Image
Point of Care 201

Finding the Target in Systemic Lupus Erythematosus

Moving From Disease Pathophysiology to Mechanism-Based Therapies

Suggested Readings

Diagnostic criteria for systemic lupus erythematosus: has the time come?

Bertsias GK, et al. Nat Rev Rheumatol. 2013;9(11):687-694.

Advances in understanding the role of type I interferons in systemic lupus erythematosus.

Crow MK. Curr Opin Rheumatol. 2014;26(5):467-474.

Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus.

Furie R, et al. Arthritis Rheumatol. 2017;69(2):376-386.

A phase 3, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits BLyS [B lymphocyte stimulator], in patients with systemic lupus erythematosus.

Furie R, et al. Arthritis Rheum. 2011;63(12):3918-3930.

The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus.

Lewis MJ, Jawad AS. Rheumatology (Oxford).

Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study.

Merrill JT, et al. Arthritis Rheumatol. 2018;70(2):266-276.

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Navarra SV, et al. Lancet. 2011;377(9767):721-731.

Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial.

Zimmer R, et al. Ann Rheum Dis. 2013;72(11):1830-1835.

Activity
Finding the Target in Systemic Lupus Erythematosus

Moving From Disease Pathophysiology to Mechanism-Based Therapies

Relevant Resources

Clinical Updates in Systemic Lupus Erythematosus

Improved Diagnostic and Management Strategies

Advances in Immunosupressive Therapy for Solid Organ Transplantation

Long-Term Management Strategies to Improve Patient Outcomes

Clinical Updates on the Management of Gout

Evidence-Based Strategies for Improved Patient Outcomes

Managing Gout in Primary Care

Evolving Strategies for Diagnosis and Long-Term Management

Improving Outcomes in Rheumatoid Arthritis

Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms

Clinical Updates in Rheumatoid Arthritis

Evolving Treatment Algorithms and Expert Perspectives on Biosimilars

Going Deeper on Atopic Dermatitis

Pathophysiology to the Management of Moderate-to-Severe Disease

Looking Beneath The Surface In Atopic Dermatitis

Targeting Immune Dysregulation and Delivering Comprehensive Care

Evolving Treatment Paradigms For Rheumatoid Arthritis

Translating Comprehensive Patient Evaluations Into Personalized Therapy

Clinical Updates in Rheumatoid Arthritis

New Perspectives on Targeting Remission and Individualizing Therapy

A Better Look at Rheumatoid Arthritis

Using Imaging to Improve Patient Outcomes

Clinical Issues in Rheumatoid Arthritis

Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs

Pathways to Better Outcomes in Systemic Lupus Erythematosus

Translating Pathophysiology into Targeted Treatments

The Big Picture of IBD

An Interactive Experience Highlighting Recent Clinical Advances

Clinical Issues in Rheumatoid Arthritis

Debates & Discussions on the Evolving Role of JAK Inhibitors

Clinical Issues in Rheumatoid Arthritis

The Evolving Role of JAK Inhibitors